NASDAQ:TIL - Nasdaq - US45783C2008 - Common Stock - Currency: USD
22.12
-1.89 (-7.87%)
The current stock price of TIL is 22.12 USD. In the past month the price decreased by -8.33%. In the past year, price increased by 88.9%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 19.97 | 357.10B | ||
AMGN | AMGEN INC | 15.29 | 162.72B | ||
GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
NTRA | NATERA INC | N/A | 21.43B | ||
BIIB | BIOGEN INC | 8.54 | 20.49B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Instil Bio, Inc. is a clinical-stage biopharmaceutical company engaged in developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte therapies for the treatment of patients with cancer. The company is headquartered in Dallas, Texas and currently employs 49 full-time employees. The company went IPO on 2021-03-19. The firm seeks to in-license/acquire and develop novel therapeutic candidates in diseases with significant unmet medical need. Its first such program is an engineered tumor infiltrating lymphocyte (TIL), cell therapy for the treatment of cancer. The company is engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor (CoStAR), platform. The firm's lead CoStAR-TIL product candidate, ITIL-306, expresses a CoStAR molecule designed to recognize folate receptor alpha (Fra), a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC and renal cancer. CAR-T and TCR-T therapies are cell products composed of T cells that have been genetically engineered to recognize a specific cancer-related antigen on the surface of tumor cells.
INSTIL BIO INC
3963 Maple Avenue, Suite 350
Dallas TEXAS 75219 US
CEO: Bronson Crouch
Employees: 49
Company Website: https://instilbio.com/
Phone: 19724993350
The current stock price of TIL is 22.12 USD. The price decreased by -7.87% in the last trading session.
The exchange symbol of INSTIL BIO INC is TIL and it is listed on the Nasdaq exchange.
TIL stock is listed on the Nasdaq exchange.
8 analysts have analysed TIL and the average price target is 116.28 USD. This implies a price increase of 425.68% is expected in the next year compared to the current price of 22.12. Check the INSTIL BIO INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
INSTIL BIO INC (TIL) has a market capitalization of 144.44M USD. This makes TIL a Micro Cap stock.
INSTIL BIO INC (TIL) currently has 49 employees.
INSTIL BIO INC (TIL) has a support level at 19.85 and a resistance level at 23.42. Check the full technical report for a detailed analysis of TIL support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
TIL does not pay a dividend.
INSTIL BIO INC (TIL) will report earnings on 2025-03-19, after the market close.
INSTIL BIO INC (TIL) does not have a PE ratio as the earnings reported over the last twelve months were negative (-11.56).
The outstanding short interest for INSTIL BIO INC (TIL) is 13.13% of its float. Check the ownership tab for more information on the TIL short interest.
ChartMill assigns a technical rating of 3 / 10 to TIL. When comparing the yearly performance of all stocks, TIL is one of the better performing stocks in the market, outperforming 92.27% of all stocks.
ChartMill assigns a fundamental rating of 2 / 10 to TIL. The financial health of TIL is average, but there are quite some concerns on its profitability.
Over the last trailing twelve months TIL reported a non-GAAP Earnings per Share(EPS) of -11.56. The EPS increased by 56.87% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -27.58% | ||
ROE | -42.63% | ||
Debt/Equity | 0.47 |
ChartMill assigns a Buy % Consensus number of 83% to TIL. The Buy consensus is the average rating of analysts ratings from 8 analysts.